Inactive Instrument

Basilea Pharmaceutica AG Share Price Xetra

Equities

PK5

CH0011432447

Biotechnology & Medical Research

Financials

Sales 2024 * 182M 202M 188M 15.97B Sales 2025 * 198M 219M 204M 17.32B Capitalization 471M 522M 486M 41.27B
Net income 2024 * 26M 28.77M 26.81M 2.28B Net income 2025 * 29M 32.09M 29.9M 2.54B EV / Sales 2024 * 2.9 x
Net Debt 2024 * 56.76M 62.82M 58.53M 4.97B Net Debt 2025 * 12.51M 13.84M 12.9M 1.1B EV / Sales 2025 * 2.45 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
16.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.61%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 31/08/14
Director of Finance/CFO 50 31/12/08
Chief Tech/Sci/R&D Officer 60 30/04/18
Members of the board TitleAgeSince
Director/Board Member 71 26/04/17
Director/Board Member 66 31/12/21
Director/Board Member 69 08/04/13
More insiders
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company